Beigene Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BEIGENE, and what generic alternatives to BEIGENE drugs are available?
BEIGENE has one approved drug.
There are twelve US patents protecting BEIGENE drugs.
There are sixty-six patent family members on BEIGENE drugs in thirty countries and thirteen supplementary protection certificates in twelve countries.
Summary for Beigene
| International Patents: | 66 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Beigene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,884,674 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,911,386 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,851,437 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beigene Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201808298 | ⤷ Subscribe |
| Cyprus | 1118834 | ⤷ Subscribe |
| China | 104884458 | ⤷ Subscribe |
| China | 116478165 | ⤷ Subscribe |
| Serbia | 55770 | ⤷ Subscribe |
| Cyprus | 2022004 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beigene Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2989106 | C202230011 | Spain | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122 |
| 2989106 | 22C1010 | France | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1576 20211123 |
| 2989106 | C02989106/01 | Switzerland | ⤷ Subscribe | FORMER OWNER: BEIGENE, LTD., KY |
| 2989106 | 2022C/508 | Belgium | ⤷ Subscribe | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
| 2989106 | 2290500-4 | Sweden | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1576 20211123 |
| 2989106 | 122022000013 | Germany | ⤷ Subscribe | PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 20211122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
